Compare Biogen Inc (BIIB) vs Bank of Montreal (BMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Bank of Montreal — how do they compare? Biogen Inc trades at $202.05 (market cap $30.13B), while Bank of Montreal trades at $182.27 (market cap $126.83B). The key difference: Bank of Montreal is far larger — about 4.2× Biogen Inc's market cap, and Bank of Montreal pays a 2.69% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | BMO | |
|---|---|---|
Market Cap | $30.13B | $126.83B |
Sector | Health | Financials |
52-Week High | $216.63 | $183.65 |
52-Week Low | $128.93 | $112.54 |
Enterprise Value | $37.20B | — |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
BMO trades at $181.91, up 0.2% today, with a bullish technical signal from moving averages and support near $181. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.68 exceeding the $2.54 estimate. Revenue grew to $36.10B in 2025, and net income margin improved to 24.12%. Recent news includes the sale of Moneris for $1.44B and the launch of new ETNs with REX Shares.
Outlook is supported by consistent earnings performance and strategic initiatives, but risks include interest rate sensitivity and macroeconomic pressures. Analysts are divided with a Hold consensus, reflecting balanced optimism and caution. The stock's valuation at a P/E of 19.41 appears reasonable given profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →
